- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04225923
A Study for Kidney Transplant Recipients at High-Risk of Cytomegalovirus Infection
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of NPC-21 for Kidney Transplant Recipients at High-Risk of Cytomegalovirus Infection
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Aichi
-
Nagakute, Aichi, Japan
- Research site_204
-
Nagoya, Aichi, Japan
- Research site_201
-
Toyoake, Aichi, Japan
- Research site_202
-
-
Hyogo
-
Kobe, Hyogo, Japan
- Research site_206
-
Nishinomiya, Hyogo, Japan
- Research site_205
-
-
Kanagawa
-
Kawasaki-shi, Kanagawa, Japan
- Marianna University School of Medicine
-
-
Kumamoto
-
Kumamoto-shi, Kumamoto, Japan
- Research site_212
-
-
Okinawa
-
Tomigusuku-shi, Okinawa, Japan
- Research site_215
-
-
Osaka
-
Osaka-shi, Osaka, Japan
- Osaka Metropolitan University Hospital
-
Osaka-shi, Osaka, Japan
- Research site_211
-
Osaka-shi, Osaka, Japan
- Research site_214
-
Suita, Osaka, Japan
- Research site_208
-
-
Tochigi
-
Shimotsuke, Tochigi, Japan
- Research site_203
-
-
Tokyo
-
Hachioji-shi, Tokyo, Japan
- Research site_213
-
-
-
-
Arizona
-
Phoenix, Arizona, United States, 85054
- Mayo Clinic - Scottsdale
-
-
California
-
La Mesa, California, United States, 91942
- California Institute of Renal Research
-
-
Georgia
-
Atlanta, Georgia, United States, 30309
- Piedmont Healthcare
-
Augusta, Georgia, United States, 30912
- Augusta University Medical Center
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48084
- University of Michigan
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University School of Medicine
-
-
Nebraska
-
Omaha, Nebraska, United States, 68198
- University of Nebraska Medical Center
-
-
Ohio
-
Cincinnati, Ohio, United States, 45219
- The Christ Hospital
-
Cincinnati, Ohio, United States, 45219
- University of Cincinnati College of Medicine
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic
-
-
Texas
-
Dallas, Texas, United States, 75390
- University of Texas Southwestern
-
Dallas, Texas, United States, 75235
- Renal Disease Research Institute
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53792
- University of Wisconsin - Madison
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female patients 18 to 75 years of age in the United States or 20 to 75 years of age in Japan at the time of obtaining informed consent.
- Patients must be CMV seronegative pre-transplant and scheduled to receive or have received (within 7 days prior to first study drug administration) a first kidney transplant from a CMV seropositive donor.
- Patients must be willing and able to give written informed consent for participation in the study.
- Patients must be eligible to undergo kidney transplantation from a living or deceased donor, as per institutional standards.
- Patients must agree with contraception by using appropriate contraceptive measures.
Exclusion Criteria:
- Patients who have received a previous solid organ transplantation or hematopoietic stem cell transplantation.
- Patients who receive a multi-organ transplant.
- Patients who have CMV disease or CMV viremia at Screening.
- Patients who have a positive donor-specific antibody within 90 days prior to Randomization confirmed via medical records.
- Patients whose body weight is more than 120 kg at Screening.
Patients who have received the following anti-CMV therapy within 7 days prior to Randomization and/or plan to receive the following anti-CMV therapy during the study:
・ Anti-CMV agents (eg, foscarnet, ganciclovir, valganciclovir, letermovir, high dose acyclovir, high dose valacyclovir, high dose famciclovir, or cidofovir).
Note: The use of anti-CMV agents per local standard of care during the Rescue Phase of the study is permitted.
Note: The use of anti-herpes simplex virus and anti-varicella zoster virus prophylaxis for at-risk patients is recommended (as long as the doses are below the one specified above).
Patients who have received the following therapy within 28 days prior to Randomization and/or plan to receive the following anti-CMV therapy during the study:
- CMV hyperimmune globulin (eg, CytoGam).
- Intravenous immunoglobulin.
- Plasmapheresis (receipt prior to first study drug administration is acceptable).
- Patients with a history of a serious drug allergy to proteins, immunoglobulins, transfusions, or vaccines or any excipient of the NPC-21 formulation.
- Patients with severe hepatic insufficiency at Screening (eg, Child-Pugh Class C).
- Patients with active and untreated hepatitis B virus or hepatitis C virus, as documented as part of the pre-transplant screening.
- Patients with known human immunodeficiency virus infection, based on medical records serology.
- Patients with any uncontrolled infection at Randomization or a history of serious and uncontrolled infection within 6 months prior to Randomization.
- Patients who are pregnant or lactating.
- Patients with a history of malignancy within 5 years prior to Randomization other than curatively treated in situ cervical carcinoma, cutaneous basal cell carcinoma, or cutaneous squamous cell carcinoma.
- Patients with a history of alcohol or drug abuse or dependence within 1 year prior to Randomization that, in the opinion of the Investigator, would preclude study participation.
- Patients who have previously participated in this study or any other study involving NPC-21.
- Patients who have previously participated or are currently participating in any study involving the administration of a CMV vaccine or another CMV investigational agent.
- Patients who have participated in another interventional clinical study and received another investigational product (ie, not approved by the Food and Drug Administration in the United States or the Ministry of Health, Labour and Welfare in Japan) within 90 days before Randomization.
- Patients who are unable or unwilling, in the opinion of the Investigator, to comply with the protocol.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: NPC-21 Low dose
NPC-21 (Low dose) will be administered
|
NPC-21 will be administered via an approximately 60-minute intravenous infusion
|
Experimental: NPC-21 High dose
NPC-21 (High dose) will be administered
|
NPC-21 will be administered via an approximately 60-minute intravenous infusion
|
Placebo Comparator: NPC-21 Placebo
Placebo (normal saline) will be administered
|
Placebo will be administered via an approximately 60-minute intravenous infusion
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of CMV disease or CMV viremia
Time Frame: 16 weeks
|
Percentage of patients with adjudicated CMV disease or CMV viremia through 16 weeks post-transplant
|
16 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of CMV disease or CMV viremia
Time Frame: 28 weeks
|
Percentage of patients with adjudicated CMV disease or CMV viremia.
|
28 weeks
|
Incidence of CMV disease
Time Frame: 28 weeks
|
Percentage of patients with adjudicated CMV disease
|
28 weeks
|
Incidence of CMV viremia
Time Frame: 28 weeks
|
Percentage of patients with adjudicated CMV viremia.
|
28 weeks
|
Time to detectable CMV disease or CMV viremia
Time Frame: 28 weeks
|
28 weeks
|
|
Time to detectable CMV disease
Time Frame: 28 weeks
|
28 weeks
|
|
Time to detectable CMV viremia
Time Frame: 28 weeks
|
28 weeks
|
|
Amount of CMV DNA
Time Frame: 28 weeks
|
28 weeks
|
|
Incidence and duration of anti-CMV therapy during the Rescue Phase
Time Frame: 28 weeks
|
28 weeks
|
|
Changes in EQ-5D-5L score from Baseline
Time Frame: 28 weeks
|
28 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NPC-21-2
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cytomegalovirus Disease
-
Merck Sharp & Dohme LLCCompletedCytomegalovirus Infection | Cytomegalovirus DiseaseJapan
-
University of Sao Paulo General HospitalCompletedCytomegalovirus DiseaseBrazil
-
The George Washington University Biostatistics...Eunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedCongenital Cytomegalovirus Infection | Maternal Cytomegalovirus InfectionUnited States
-
Assistance Publique - Hôpitaux de ParisTerminatedCytomegalovirus Infection | Viral DiseaseFrance
-
Foundation IRCCS San Matteo HospitalFondazione Regionale per la Ricerca Biomedica (FRRB) - Regione LombardiaUnknownCongenital Cytomegalovirus Infection | Maternal Cytomegalovirus InfectionItaly
-
Rabin Medical CenterCompletedCongenital Cytomegalovirus InfectionIsrael
-
National Institute of Allergy and Infectious Diseases...Completed
-
BiotestActive, not recruitingCongenital Cytomegalovirus InfectionGermany
-
Central Hospital, Nancy, FranceCompletedCongenital Cytomegalovirus InfectionFrance
-
Jun ZhangNational Natural Science Foundation of China; Merck Sharp & Dohme LLCCompletedCongenital Cytomegalovirus Infection | Cytomegalovirus Infection ReactivationChina
Clinical Trials on NPC-21 Low dose
-
Veradermics, Inc.RecruitingWarts | Common Wart | Verruca VulgarisUnited States
-
NobelpharmaCompletedAutism Spectrum Disorder | Sleep Disorders
-
HvivoPfizerRecruiting
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingRecurrent Mantle Cell Lymphoma | Refractory Mantle Cell LymphomaUnited States
-
Emory UniversityNational Cancer Institute (NCI)TerminatedPneumonia | Coronavirus Infection in 2019 (COVID-19) | Severe Acute Respiratory Syndrome (SARS) PneumoniaUnited States
-
Beijing Northland Biotech. Co., Ltd.CompletedSafety and Efficacy Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction.InfarctionAcute Myocardial InfarctionChina
-
MedImmune LLCCompletedNon-alcoholic Fatty Liver Disease (NAFLD) | Non-alcoholic Steatohepatitis (NASH)United States, Puerto Rico
-
Lucozade Ribena SuntoryKing's College LondonCompletedPostprandial PeriodUnited Kingdom
-
Postgraduate Institute of Medical Education and...Completed
-
Indonesia UniversityMedika Natura Sdn BhdCompleted